Simepdekinra clinical trials
Also written LY4100511 and DC-853.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2023
How each study uses simepdekinra is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 5 |
| 2025 | 1 |
Who runs them
Industry 7 · Other 0
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (5) · Eli Lilly and Company (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses simepdekinra is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach AcidTerminatedPhase 1Eli Lilly and CompanyNCT06916143Written as LY4100511
- A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque PsoriasisCompletedPhase 2DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06602219Written as LY4100511
- A Study to Assess LY4100511 (DC-853) in Healthy Adult ParticipantsCompletedPhase 1DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06345794Written as LY4100511 (DC-853)
- A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06937411Written as LY4100511
- A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian ParticipantsCompletedPhase 1DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06311656Written as LY4100511 (DC-853)
- A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy ParticipantsCompletedPhase 1DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06503679Written as LY4100511 (DC-853) Dose 1
- A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male ParticipantsCompletedPhase 1DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyNCT06627088Written as LY4100511 (DC-853)
Codes
What other systems call simepdekinra · ClinicalTrials.gg INT015723
- UNII (FDA) 8U4A6H2TWUSIMEPDEKINRAOne source FDA
- NCI Thesaurus C215768SimepdekinraOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8U4A6H2TWU | SIMEPDEKINRA | One source FDA |
| NCI Thesaurus | C215768 | Simepdekinra | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.